# Safety, Tolerability, and Pharmacokinetics, of Single and Multiple Ascending Doses of FP-020 in Healthy Adult Volunteers

> **NCT06334211** · PHASE1 · COMPLETED · sponsor: **Foresee Pharmaceuticals Co., Ltd.** · enrollment: 64 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** FP-020
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT06334211
- **Lead sponsor:** Foresee Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-04-16
- **Primary completion:** 2024-09-20
- **Final completion:** 2024-09-20
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2024-11-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06334211

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06334211, "Safety, Tolerability, and Pharmacokinetics, of Single and Multiple Ascending Doses of FP-020 in Healthy Adult Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06334211. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*